PTEN and prostate carcinoma: PI3K-AKT signaling could be antagonized by the tumor suppressor phosphatase and tensin homolog (PTEN) which was reported to be usually mutated in several sorts of neoplasms, such as the endometrium, skin, brain, and prostate cancers [36–38].